Hitachi announced about the agreement where apceth Biopharma GmbH will join the Hitachi Chemical’s PCT services. The firm manufactures gene and cell therapy products. America and Europe are its major market. The firm has 2 manufacturing units in Munich, Germany. As per this agreement Hitachi will acquire manufacturing units and some area of cleanroom.
The coming together of both firms will strengthen their global market presence and help them to be the second largest in their of gene and cell therapy market. As per Christine Guenther, CEO of apceth Biopharma, coming together will combine their strength and manufacture complex cell and gene therapies for various regions such as, Asia, North America and Europe. Also, it would help supply patients globally with highly advanced and high-quality cell and gene therapies.
As per the agreement, manufacturing platforms three facilities in which two are located in Yokohama, Japan and Mountain View, CA. Another one under construction is located in New Jersey. The New Jersey facility is expected to start commercial manufacturing by second quarter of 2019. Coming together of both firms will positively impact the PCT services globally.
About Hitachi Chemicals: Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), is a solely owned subsidiary of Hitachi Chemical Company, Ltd. (Hitachi Chemical) representing Hitachi Chemical’s Regenerative Medicine Business Sector in the United States. HCATS holds nearly two decades of experience entirely focused on the cell therapy industry. It offers contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including commercial manufacturing, manufacturing development, and clinical manufacturing.
— Vasundhra Singh,
Assistant Research Executive,